MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease

    E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Marshall, M. Korell, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…
  • 2024 International Congress

    Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)

    G. Cordeiro, I. Peixoto, H. Gama, L. Magalhães, J. Moreira, J-F. Rocha, J. Holenz (Trofa, Portugal)

    Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…
  • 2024 International Congress

    Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)

    B. Bicknell, S. Tilley, G. Herkes, A. Liebert (, Westmead, Australia)

    Objective: To determine the effectiveness of photobiomodulation (light therapy) on MDS-UPDRS-III scores over a five-year period Background: As a progressive neurodegenerative disease, worsening of motor…
  • 2024 International Congress

    Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention

    T. Oosterhof, E. Mitchell, A. Ascherio, B. Bloem, K. van Dijk, B. Dijkstra, L. Kaufmann, R. Lathey, E. Macklin, A. Navangul, A. Pijpers, H. Rowbotham, R. Schneider, M. Schwarzschild, N. de Vries, A. Noyce, S. Darweesh (Nijmegen, Netherlands)

    Objective: To determine the feasibility and preliminary efficacy of a remote exercise intervention in prodromal Parkinson’s disease (PD). Background: Disease-slowing interventions have been ineffective in…
  • 2024 International Congress

    Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies

    F. Eriksson, J. Fälting, E. Nordström, L. Söderberg, M. Johannesson, O. Zachrisson, P. Appelkvist, C. Möller, G. Osswald, M. Björklund, T. Odergren, E. Boström, E. Button, D. Sunnemark (Stockholm, Sweden)

    Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…
  • 2024 International Congress

    Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use

    D. Santos Garcia, W. Jost, M. José Martí, M. Fonseca, C. Denecke Muhr, I. Pijuan (A Coruña, Spain)

    Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…
  • 2024 International Congress

    Using Algorithm Guided Programming to Treat Parkinson’s Disease Patients Implanted with Deep Brain Stimulation

    C. Luca, Y. Lin, K. Su, J. Jagid, V. Torres, R. Shivacharan, L. Moore (Miami, USA)

    Objective: To compare acute outcomes from Parkinson’s disease patients implanted with Deep Brain Stimulation (DBS) programmed using Algorithm Guided Programming (AGP) versus conventional, standard of…
  • 2024 International Congress

    Gender Differences Following Bilateral STN DBS Surgery in Parkinson’s Disease

    E. Israel, I. Dustin, D. Ehrlich (Bethesda, USA)

    Objective: To examine DBS surgery outcomes within the Deep Brain Stimulation (DBS) PD cohort at the NIH among males and females and improve our understanding…
  • 2024 International Congress

    Evaluating Clinical Practices of General Neurologists and Movement Disorder Specialists Based on 2020 AAN Parkinson Disease Quality Metrics

    C. Marshall, P. Vaswani (Philadelphia, USA)

    Objective: To evaluate and compare clinical practices of providers caring for patients with Parkinson’s disease utilizing searchable proxies of published quality metrics. Background: In 2020,…
  • 2024 International Congress

    Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease

    G. Agyeah, J. Ghelfi, L. Gallucci, A. Rakovic, P. Antony, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

    Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…
  • « Previous Page
  • 1
  • …
  • 275
  • 276
  • 277
  • 278
  • 279
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley